ZYBERNO
Stock Report
Updated Sep 1, 2026

VOR BIOPHARMA INC. (VOR)

Healthcare • NASDAQ

$22.65

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
VOR BIOPHARMA INC. (VOR) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-737.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

VOR BIOPHARMA INC. (VOR) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, VOR generated -$150.34M in Owner Earnings. Capital was deployed as follows: $758.00K invested in capital expenditures. Reinvestment rate: 1.8%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:22.65
Market Cap:$1.23B

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$766.77M

Price Action & Momentum (1)

% of 52-Week High:45.3%
B. Profitability Assessment

Return Metrics (4)

ROA:154.2%
Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-13.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$338.94
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:93.7%
Latest Earnings Filed:2026-08-11
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:19.15x
Quick Ratio:19.15x
Cash Ratio:18.78x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:450,293,000.00
Cash And Cash Equivalents:466,100,000.00
Long Term Debt:$2.54M
Net Debt:-$463.22M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$147.08M

Bottom Line Performance (3)

$627.78M
Income Before Tax:$0.00
Ebitda Ttm:-144,165,000.00

Operating Expenses (5)

Operating Expenses:147,080,000.00
R And D Expense:76,847,000.00
Sga Expense:70,233,000.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$481.05M
Current Assets:$475.11M
Ppe Net:648,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:681,250,000.00
Current Liabilities:24,814,000.00
Long Term Debt:$2.54M
Short Term Debt:$335.00K

Equity & Capital (3)

Equity:-$200.20M
Retained Earnings:-$1.44B
Common Stock:800,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:20,481,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:9,399,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$149.89M-$150.65M

Investment Activities (2)

Investing Cash Flow:-$263.24M
Capital Expenditures Ttm:758,000.00

Financing Activities (3)

Financing Cash Flow:$74.87M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:70,106,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,915,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-76.77
-$76.77
Earnings Per Share Ttm:$11.56

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.63

Book Value & Capital (2)

Book Value Per Share:-$3.69
Cash Per Share:8.58

Dividend Policy (1)

Dividend Payout Ratio:0.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$150.34M

Damodaran Growth Analysis (2)

Reinvestment Rate:1.8%
Fundamental Growth Rate (g):-13.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-29.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:VOR
Company Name:VOR BIOPHARMA INC.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:54.30M
Shares Outstanding Basic:54.30M
Shares Outstanding Diluted:54.30M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 13:08:21 UTC
Data Timestamp:2026-09-01T13:08:21.334721
Scroll to Top